WOBURN, Mass. & AURORA, Colo.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Dr. Stephen Dilly has joined its Board of Directors.
Dr. Dilly brings three decades of executive management experience in the biopharmaceutical industry. Most recently, Dr. Dilly served as CEO and Board Member of Aimmune Therapeutics, where he currently serves as Special Advisor. Dr. Dilly has served in executive roles at Genentech, Chiron and SmithKline Beecham and has been associated with the development and launch of several marketed drugs. He holds an M.B.B.S. from the University of London and a Ph.D. in Cardiac Physiology from University of London.
Dr. Dilly also currently serves as Board Chairman of Cognoa, a pediatric behavioral health company, Board Chairman of DNAtrix, developing virus-driven immunotherapies, and is a Board member of Sangamo Therapeutics and Adjuvance Technologies.
IM Therapeutics was founded by world-class physician scientists based on seminal research showing that blocking action of certain human leukocyte antigen (HLA) gene variants can block the autoimmune response. The Company demonstrated this in a proof-of-concept Phase 1b human study in DQ8-positive type 1 diabetes.
“We are excited to bring Stephen on board and gain from his experience in advancing new drugs through the clinic and steering corporate strategy at our stage of growth,” said Nandan Padukone, Ph.D., CEO of IM Therapeutics. “Stephen is a great addition to our team as we build our pipeline across autoimmune diseases.”
“I am truly intrigued by the underlying biology and the drug development approach against HLA targets at IM Therapeutics,” said Dr. Dilly. “It is exciting to see the team’s achievements to-date and the promise to bring personalized therapies in type 1 diabetes, celiac disease and other autoimmune diseases,” he added.
IM Therapeutics is developing personalized medicines for autoimmune diseases by building oral drug therapies against human leukocyte antigen (HLA) variants that confer high risk of disease. The Company platform screens millions of compounds for optimal docking within HLA proteins together with rational drug design and bioassays to develop targeted therapeutic candidates. Its lead drug, IMT-002, is directed at HLA DQ8 activity for treatment of type 1 diabetes. The Company is building a broad pipeline of drugs against HLA targets in autoimmune disorders including celiac disease. http://imtherapeutics.com/